John Burt takes on leadership of PolyTherics
pharmafile | June 23, 2011 | Appointment | Research and Development | appointment, research and development
PolyTherics has promoted John Burt from chief business officer to chief executive.
Prior to joining PolyTherics, which applies precision chemistry to develop improved protein and peptide-based drugs, John was previously chief executive of Thiakis.
He co-founded that company with Professor Steve Bloom of Imperial College in 2004 and was subsequently acquired by Wyeth in 2008.
John takes over from Dr Keith Powell, who steps down from the role and the biopharmaceutical company’s board to pursue other interests.
Keith said: “It has been a pleasure to work with such a dedicated team and with Steve Brocchini, PolyTherics’ chief scientific officer and one of its founders, in particular.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






